Novel Use of Autologous Cell Therapy in Ischemic Heart Failure
Tzvi Fishkin1, Riyaz Khan2, Angelo Materia2
1From the Department of Cardiology, Nassau University Medical Center, East Meadow, NY.
Insights
Cell therapy shows promise for heart failure, offering potential to reverse cardiac remodeling. While not yet standard, research indicates safety and benefits for patient mortality and quality of life.
Area of Science:
- Cardiology
- Regenerative Medicine
- Stem Cell Therapy
Background:
- Heart failure remains a leading cause of mortality despite advances in guideline-directed medical therapy.
- Persistent symptoms in heart failure patients necessitate the development of novel therapeutic strategies.
- Adverse cardiac remodeling is a key pathological feature of heart failure.
Purpose of the Study:
- To explore the potential of cell therapy in managing heart failure.
- To investigate the capacity of cell therapy to reverse adverse cardiac remodeling.
- To assess the safety and efficacy of pluripotent stem cells in heart failure treatment.
Main Methods:
- Preclinical studies and clinical trials investigating pluripotent stem cells.
- Evaluation of cell therapy for both ischemic and nonischemic heart failure etiologies.
- Analysis of trial data for safety, mortality, and quality of life endpoints.
Main Results:
- Several pivotal trials have demonstrated the safety of cell therapy in heart failure patients.
- While primary endpoints were not met, some trials indicated potential benefits in mortality and quality of life.
- Cell therapy has not yet become a standard treatment for heart failure.
Conclusions:
- Cell therapy holds significant potential for managing heart failure, including reversing cardiac remodeling.
- Continued research is crucial to establish cell therapy as a viable treatment option.
- Cell therapy may offer future therapeutic benefits for severe heart failure cases.
Abstract:
Heart failure management is a rapidly progressing field that has dramatically changed over the past several decades. The development of guideline-directed medical therapy has allowed those with heart failure with reduced ejection fraction to have far better clinical outcomes. Despite these advances, heart failure remains a very prevalent and morbid condition with hundreds of thousands of deaths attributed to heart failure in the United States each year. The need for novel therapeutics remains vital to improve outcomes and help those who continue to have persistent symptoms despite optimal medical therapy. The advent of cell therapy for heart failure has sparked great interest over the years due to its potential to not just temper, but reverse adverse cardiac remodeling. Many preclinical and clinical trials have explored the use of pluripotent stem cells for both ischemic and nonischemic etiologies of heart failure. There have been several pivotal trials in the world of cell therapy that have failed to meet their primary endpoints but have still paved the way to show both the safety of cell therapy and signal towards mortality and quality of life benefits. Although cell therapy has not yet been successful to become a staple of heart failure management, the field continues to be studied and signals potential to have a place in the management of even the sickest heart failure patients.
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:22Heart Failure VI: Adjunct Therapies
01:29Cardiomyopathy V: Interprofessional Care